Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H10ClN3O3 |
Molecular Weight | 315.7117 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(c(c1)C2=NCC(=Nc3ccc(cc32)N(=O)=O)O)Cl
InChI
InChIKey=DGBIGWXXNGSACT-UHFFFAOYSA-N
InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
Molecular Formula | C15H10ClN3O3 |
Molecular Weight | 315.7117 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure
and antipanic effects is unknown, although it is believed to be related to its ability to
enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory
neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
0.06 nM [EC50] | |||
Target ID: CHEMBL2095172 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598 |
57.0 µM [EC50] | ||
Target ID: CHEMBL2111413 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25798598 |
40.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | KLONOPIN Approved UseINDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy.
Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date1.71071996E11 |
|||
Primary | KLONOPIN Approved UseINDICATIONS & USAGE Seizure Disorders: Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and . In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy.
Panic Disorder: Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder. Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Launch Date1.71071996E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 ng/mL |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3 ng/mL |
0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
102 ng × h/mL |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
339 ng × h/mL |
0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 h |
0.5 mg 3 times / day steady-state, oral dose: 0.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
15% |
0.5 mg single, oral dose: 0.5 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLONAZEPAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2 mg single, intramuscular Dose: 2 mg Route: intramuscular Route: single Dose: 2 mg Sources: |
healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: |
|
2 mg single, intravenous Dose: 2 mg Route: intravenous Route: single Dose: 2 mg Sources: |
healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: |
|
2 mg single, oral |
healthy, 30 years (range: 23–50 years) n = 12 Health Status: healthy Age Group: 30 years (range: 23–50 years) Sex: M+F Population Size: 12 Sources: |
|
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Disc. AE: Somnolence, Depression... AEs leading to discontinuation/dose reduction: Somnolence (7%) Sources: Depression (4%) Nervousness (1%) Dizziness (1%) Ataxia (1%) Intellectual disability (1%) |
6 mg 1 times / day steady, oral Studied dose Dose: 6 mg, 1 times / day Route: oral Route: steady Dose: 6 mg, 1 times / day Sources: |
unhealthy |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Ataxia | 1% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Dizziness | 1% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Intellectual disability | 1% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Nervousness | 1% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Depression | 4% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Somnolence | 7% Disc. AE |
1.5 mg 1 times / day multiple, oral Recommended Dose: 1.5 mg, 1 times / day Route: oral Route: multiple Dose: 1.5 mg, 1 times / day Sources: |
unhealthy n = 574 Health Status: unhealthy Condition: seizure disorders Population Size: 574 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
weak | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
Page: 2.0 |
yes | |||
yes | yes (pharmacogenomic study) Comment: The statistical analysis displayed significant association between the patients’ CYP3A4 expression and the stable plasma concentrations of clonazepam normalized by the dose and the patient’s bodyweight. |
PubMed
Title | Date | PubMed |
---|---|---|
Letter: Clonazepam in the treatment of drug-induced dyskinesia. | 1975 Feb 1 |
|
Pharmacological options for the treatment of Tourette's disorder. | 2001 |
|
LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports. | 2001 |
|
Sleep disorders in patients with Parkinson's disease: epidemiology and management. | 2001 |
|
[Clonazepam in the treatment of labile arterial hypertension in the elderly]. | 2001 |
|
Treatment of typical absence seizures and related epileptic syndromes. | 2001 |
|
Tourette syndrome: clinical characteristics and current management strategies. | 2001 |
|
Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis. | 2001 |
|
[Clonazepam in therapy of neurogenic syncopal states]. | 2001 |
|
Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. | 2001 Apr |
|
Random total antiepileptic drug levels and seizure control during pregnancy. | 2001 Apr |
|
Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. | 2001 Apr |
|
Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. | 2001 Apr |
|
Carbamazepine treatment of corticosteroid-induced mood disorder. | 2001 Aug |
|
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. | 2001 Aug |
|
Mitochondria recycle Ca(2+) to the endoplasmic reticulum and prevent the depletion of neighboring endoplasmic reticulum regions. | 2001 Aug 3 |
|
[Primary orthostatic tremor: slow harmonic component as responsible of inestability]. | 2001 Aug-Sep |
|
Pharmacoepidemiologic investigation of a clonazepam-carbamazepine interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients. | 2001 Dec |
|
Direct LC analysis of five benzodiazepines in human urine and plasma using an ADS restricted access extraction column. | 2001 Dec |
|
Roles for mitochondrial and reverse mode Na+/Ca2+ exchange and the plasmalemma Ca2+ ATPase in post-tetanic potentiation at crayfish neuromuscular junctions. | 2001 Dec 15 |
|
Sleep disorders. | 2001 Feb |
|
Determination of the antiepileptics vigabatrin and gabapentin in dosage forms and biological fluids using Hantzsch reaction. | 2001 Feb |
|
Focal stiff-person syndrome. | 2001 Feb |
|
[Antiepileptic drugs and neuropathic pain]. | 2001 Feb 16-28 |
|
[Cortico-subcortical electrophysiological study during the effects of benzodiazepines in patients with panic disorders]. | 2001 Feb 16-28 |
|
Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. | 2001 Jan |
|
Perioral myoclonia with absence seizures: a rare epileptic syndrome. | 2001 Jan-Mar |
|
Case report: unexplained syncope explained. | 2001 Jul |
|
Infantile status epilepticus in Tunisia. Clinical, etiological and prognostic aspects. | 2001 Jul |
|
Acquired epileptiform opercular syndrome: a case report and results of single photon emission computed tomography and computer-assisted electroencephalographic analysis. | 2001 Jul |
|
Spectrofluorimetric determination of vigabatrin and gabapentin in dosage forms and spiked plasma samples through derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole. | 2001 Jul-Aug |
|
Burning mouth syndrome after taking clonazepam. | 2001 Jul-Aug |
|
Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam. | 2001 Jun |
|
Melatonin therapy for REM sleep behavior disorder. | 2001 Jun |
|
[3H]Flunitrazepam binding to recombinant alpha1beta2gamma2S GABAA receptors stably expressed in HEK 293 cells. | 2001 May |
|
Behavioral effects of agents active at the gamma-aminobutyric acid receptor complex in the staircase paradigm. | 2001 May 18 |
|
Obstetrical and neonatal outcome following clonazepam use during pregnancy: a case series. | 2001 May-Jun |
|
Stiff leg syndrome: case report. | 2001 Nov |
|
West syndrome: the Philippine experience. | 2001 Nov |
|
Kinetic and pharmacological properties of GABA(A) receptors in single thalamic neurons and GABA(A) subunit expression. | 2001 Nov |
|
Increased [Mg2+]o reduces Ca2+ influx and disruption of mitochondrial membrane potential during reoxygenation. | 2001 Nov |
|
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. | 2001 Oct |
|
2-Arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. New potent and selective peripheral benzodiazepine receptor ligands. | 2001 Oct |
|
Effect of clonazepam treatment on antipsychotic drug-induced Meige syndrome and changes in plasma levels of GABA, HVA, and MHPG during treatment. | 2001 Oct |
|
A successful clonazepam treatment without tolerance in a patient with spontaneous oral dyskinesia. | 2001 Oct |
|
[Efficacy of anticonvulsants on acute encephalitis with refractory, repetitive partial seizures (AERRPS)]. | 2001 Sep |
|
Topiramate as a mood stabilizer. | 2001 Sep |
|
Hyperekplexia in neonates. | 2001 Sep |
|
Evaluation of polymeric nanoparticles composed of cholic acid and methoxy poly(ethylene glycol). | 2001 Sep 11 |
|
Myoclonus during prolonged treatment with sertraline in an adolescent patient. | 2001 Summer |
Patents
Sample Use Guides
Seizure Disorders: Adults: The initial dose for adults with seizure disorders should not
exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of
0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects
preclude any further increase. Maintenance dosage must be individualized for each
patient depending upon response. Maximum recommended daily dose is 20 mg. Clonazepam is available as a tablet or an orally disintegrating tablet (wafer). The tablets
should be administered with water by swallowing the tablet whole. The orally
disintegrating tablet should be administered as follows: After opening the pouch, peel
back the foil on the blister. Do not push tablet through foil. Immediately upon opening
the blister, using dry hands, remove the tablet and place it in the mouth. Tablet
disintegration occurs rapidly in saliva so it can be easily swallowed with or without water.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11698521
Clonazepam (100 nM) increased inhibitory postsynaptic current (IPSC) decay time constants in rat thalamic nuclei-the reticular nucleus (nRt) (from 44.3 to 77.9 ms, P < 0.01) but not in the ventrobasal (VB) complex..
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:53:24 UTC 2021
by
admin
on
Fri Jun 25 20:53:24 UTC 2021
|
Record UNII |
5PE9FDE8GB
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175694
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
WHO-VATC |
QN03AE01
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
NCI_THESAURUS |
C264
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
FDA ORPHAN DRUG |
243507
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
WHO-ATC |
N03AE01
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
NDF-RT |
N0000007542
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
DEA NO. |
2737
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
LIVERTOX |
224
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
||
|
FDA ORPHAN DRUG |
82794
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2802
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
CLONAZEPAM
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
2598
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | RxNorm | ||
|
703
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
Clonazepam
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
DB01068
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
1622-61-3
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
D002998
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
M3649
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | Merck Index | ||
|
1140305
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | USP-RS | ||
|
216-596-2
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
1622-61-3
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
2765
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
C28935
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
5PE9FDE8GB
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
SUB06728MIG
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
CHEMBL452
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
3265
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY | |||
|
6963
Created by
admin on Fri Jun 25 20:53:24 UTC 2021 , Edited by admin on Fri Jun 25 20:53:24 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT | |||
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MAXIMUM TOLERATED DOSE | TOXICITY |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||
ORAL BIOAVAILABILITY | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||
PROTEIN BINDING | PHARMACOKINETIC |
|
|
|||
Route of Elimination | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||